Clinical trial NCT06533553: A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD
Official title: An Open-label Phase II Study to Assess the Pharmacodynamic (PD) Effects of Dexpramipexole in Participants With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Chronic Obstructive Pulmonary Disease
Keywords: COPD
Lead sponsor: Areteia Therapeutics
Sponsor class: INDUSTRY
First posted: 2024-08-01
Enrollment: 30
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD. This study will help characterize the profile and duration of reductions of blood absolute eosinophil counts (AEC).


Eligibility criteria: Inclusion Criteria:

* Signed informed consent form prior to any study-specific procedures.
* Male or female ≥40 to ≤80 years of age at Screening Visit.
* Physician diagnosis of COPD for at least 2 years prior to the Screening Visit in accordance with the definition by the American Thoracic Society/European Respiratory Society
* Current or former smokers with a cigarette smoking history of ≥10 pack years at the Screening Visit calculated as (number of pack years = \[number of cigarettes per day/20\] multiplied by number of years smoked). Former smokers are defined as those who meet the pack-year history but have stopped smoking for at least 6 months prior to the Screening Visit.
* Spirometry: post-BD FEV1/FVC \<0.70 and post-BD FEV1 \>20% and ≤60% of predicted normal values at the Screening Visit.
* Documented history of exacerbation risk defined as exacerbation history of ≥1 moderate\* or ≥1 severe\*\* within 2 years prior to the Screening Visit.
* Background ICS-based therapy (ICS+ long-acting β2 agonist \[LABA\], or ICS + long-acting muscarinic antagonist \[LAMA\], or ICS + LAMA + LABA) for ≥12 weeks prior to enrollment with a stable dose of medication for ≥4 weeks prior to the Screening Visit.
* Evidence of an eosinophilic phenotype: Participants with blood eosinophils ≥0.30x109/L at the Screening Visit.
* Negative urine pregnancy test for women of childbearing potential (WOCBP) at the Screening and Baseline Visits.
* WOCBP (after menarche) must use e methods of birth control from the Screening Visit through the End of Study Visit..

Exclusion Criteria:

* A current diagnosis of asthma or any history of asthma diagnosis when ≥40 years of age.
* Significant pulmonary disease other than COPD (eg, α-1 antitrypsin deficiency, active tuberculosis, lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, lung cancer, clinically significant bronchiectasis, Churg-Strauss Syndrome) or another diagnosed pulmonary or systemic disease associated with elevated eosinophil counts.
* Pneumonia, upper or lower respiratory tract infection or acute exacerbation of COPD within 4 weeks prior to or during the Screening Phase.
* Treatment with a biologic investigational drug in the last 5 months prior to the Screening Visit. Treatment with non-biologic investigational drugs in the previous 30 days or five-half-lives prior to the Screening Visit, whichever is longer. Treatment with GSK3511294 (long-acting anti-interleukin-5) in the past 12 months.
* Treatment with any of the following monoclonal antibody therapies within 120 days prior to the Baseline Visit: benralizumab, dupilumab, mepolizumab, reslizumab, omalizumab, tezepelumab, or tralokinumab.
* Treatment with pramipexole (Mirapex®) within 30 days of the Baseline Visit.
* Treatment with selected drugs known to have a substantial risk of neutropenia in the past 30 days prior to the Screening Visit.
* Treatment with selected drugs known to have a substantial risk of QT prolongation in the past 30 days prior to the Screening Visit.
* Participants who are participating in the acute phase of a pulmonary rehabilitation program, ie, who started rehabilitation.
* History of malignancy that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy during the 2 years prior to the Baseline Visit.
* History of human immunodeficiency virus infection or chronic infection with hepatitis B or C.
* Neutrophil count \<2.000x109/L at the Screening Visit.
* Renal dysfunction, defined as an estimated glomerular filtration rate \<60 mL/min/1.73m2 at the Screening Visit (using the Chronic Kidney Disease Epidemiology Collaboration) formula.
* Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), \>3x the upper limit of normal (ULN), or total bilirubin \>2x ULN at the Screening Visit confirmed by a repeat abnormal measurement of the relevant value(s), at least 1 week apart.
* History of New York Heart Association class IV heart failure or last known left ventricular ejection fraction \<25%.
* Corrected QT interval by Fridericia (QTcF) interval \>450 ms for males and \>470 ms for females at the Screening Visit or QTcF ≥480 ms for participants with bundle branch block.
* Pregnant women or women breastfeeding.
* Males who are unwilling to use an acceptable method of birth control during the entire study period (ie, condom with spermicide).
* The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: Geometric mean change in the blood AEC from baseline to Week 16
timeFrame: Baseline, Week 16
Secondary outcomes:
measure: Pre-BD FEV1
timeFrame: Baseline, Week 16
measure: Post-BD FEV1
timeFrame: Baseline, Week 16
measure: St George's Respiratory Questionnaire for COPD Patients (SGRQ-C)
timeFrame: Baseline, Week 16
measure: COPD Assessment Test (CAT)
timeFrame: Baseline, Week 16
Other outcomes:
Locations:
city: Conway
country: United States
facility: Research Site US-10001-017
state: Arkansas
city: Newport Beach
country: United States
facility: Research Site US-10001-008
state: California
city: Northridge
country: United States
facility: Research Site US-10001-022
state: California
city: Westminster
country: United States
facility: Research Site US-10001-016
state: California
city: Orlando
country: United States
facility: Research Site US-10001-030
state: Florida
city: Champaign
country: United States
facility: Research Site 10001-032
state: Illinois
city: Hammond
country: United States
facility: Research Site US-10001-021
state: Indiana
city: Des Moines
country: United States
facility: Research Site US-10001-033
state: Iowa
city: Baltimore
country: United States
facility: Research Site US-10001-020
state: Maryland
city: Farmington Hills
country: United States
facility: Research Site US-10001-024
state: Michigan
city: Saint Louis
country: United States
facility: Research Site US-10001-001
state: Missouri
city: St Charles
country: United States
facility: Research Site US-10001-005
state: Missouri
city: Charlotte
country: United States
facility: Research US-10001-010
state: North Carolina
city: Charlotte
country: United States
facility: Research Site US-10001-025
state: North Carolina
city: Gastonia
country: United States
facility: Research Site US-10001-007
state: North Carolina
city: Columbus
country: United States
facility: Research Site US-10001-004
state: Ohio
city: DuBois
country: United States
facility: Research Site US-10001-002
state: Pennsylvania
city: Philadelphia
country: United States
facility: Research Site US-10001-013
state: Pennsylvania
city: East Providence
country: United States
facility: Research Site US-10001-023
state: Rhode Island
city: Rock Hill
country: United States
facility: Research Site US-10001-012
state: South Carolina
city: Corsicana
country: United States
facility: Research Site US-10001-009
state: Texas
city: Houston
country: United States
facility: Research Site US-10001-038
state: Texas
city: McKinney
country: United States
facility: Research Site 10001-026
state: Texas
Study officials:
affiliation: Temple University
name: Gerard J Criner, MD
role: PRINCIPAL_INVESTIGATOR
References: